Highbridge Capital Management LLC acquired a new stake in Sarepta Therapeutics Inc (NASDAQ:SRPT) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 20,326 shares of the biotechnology company’s stock, valued at approximately $922,000.

A number of other large investors have also recently modified their holdings of the business. Ameritas Investment Partners Inc. boosted its stake in shares of Sarepta Therapeutics by 6.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 271 shares during the last quarter. Cubist Systematic Strategies LLC boosted its stake in shares of Sarepta Therapeutics by 116.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after buying an additional 2,474 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in shares of Sarepta Therapeutics during the 3rd quarter valued at approximately $204,000. Bayesian Capital Management LP purchased a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at approximately $206,000. Finally, Strs Ohio purchased a new position in shares of Sarepta Therapeutics during the 3rd quarter valued at approximately $208,000. 82.02% of the stock is owned by institutional investors.

Sarepta Therapeutics Inc (SRPT) opened at $52.60 on Friday. Sarepta Therapeutics Inc has a one year low of $26.26 and a one year high of $57.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. The firm had revenue of $45.95 million for the quarter, compared to analysts’ expectations of $41.29 million. During the same period last year, the business posted ($0.95) earnings per share. equities analysts anticipate that Sarepta Therapeutics Inc will post -3.11 earnings per share for the current year.

SRPT has been the subject of several research analyst reports. Nomura reiterated a “buy” rating and set a $84.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, September 5th. Robert W. Baird reiterated an “outperform” rating and set a $101.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, September 6th. Needham & Company LLC reiterated a “buy” rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, September 6th. Barclays initiated coverage on Sarepta Therapeutics in a research note on Wednesday, September 6th. They set an “equal weight” rating and a $46.00 target price for the company. Finally, Credit Suisse Group increased their target price on Sarepta Therapeutics from $5.65 to $81.00 and gave the company an “outperform” rating in a research note on Thursday, September 7th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and sixteen have assigned a buy rating to the company’s stock. Sarepta Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $64.14.

In other news, CEO Douglas S. Ingram acquired 38,138 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, November 8th. The shares were purchased at an average cost of $52.44 per share, for a total transaction of $1,999,956.72. Following the completion of the purchase, the chief executive officer now directly owns 420,196 shares of the company’s stock, valued at approximately $22,035,078.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Shamim Ruff sold 11,500 shares of the firm’s stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $50.00, for a total value of $575,000.00. The disclosure for this sale can be found here. Insiders have sold 28,167 shares of company stock worth $1,497,619 over the last 90 days. 9.60% of the stock is currently owned by company insiders.

WARNING: “Highbridge Capital Management LLC Invests $922,000 in Sarepta Therapeutics Inc (SRPT) Stock” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/16/highbridge-capital-management-llc-invests-922000-in-sarepta-therapeutics-inc-srpt-stock.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Stock Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related stocks with our FREE daily email newsletter.